Abstract
Despite the compelling clinical needs in enhancing bone regeneration and the potential offered by the field of tissue engineering, the adoption of cell-based bone graft substitutes in clinical practice is limited to date. In fact, no study has yet convincingly demonstrated reproducible clinical performance of tissue-engineered implants and at least equivalent cost-effectiveness compared to the current treatment standards. Here, we propose and discuss how tissue engineering strategies could be evolved towards more efficient solutions, depicting three different experimental paradigms: (i) bioreactor-based production; (ii) intraoperative manufacturing, and (iii) developmental engineering. The described approaches reflect the need to streamline graft manufacturing processes while maintaining the potency of osteoprogenitors and recapitulating the sequence of biological steps occurring during bone development, including vascularization. The need to combine the assessment of efficacy of the different strategies with the understanding of their mechanisms of action in the target regenerative processes is highlighted. This will be crucial to identify the necessary and sufficient set of signals that need to be delivered at the injury or defect site and should thus form the basis to define release criteria for reproducibly effective engineered bone graft substitutes.
References
1.
Bates P, Ramachandran M: Bone injury, healing and grafting; in Ramachandran M (ed): Basic Orthopaedic Sciences. The Stanmore Guide. London, Hodder Arnold, 2007, pp 123–134.
2.
Einhorn TA: The cell and molecular biology of fracture healing. Clin Orthop Relat Res 1998; 355(suppl):S7–S21.
3.
Zimmermann G, Müller U, Löffler C, Wentzensen A, Moghaddam A: Therapieerfolg bei atrophen Tibiaschaftpseudarthrosen Bone Morphogenetic Protein 7 (BMP 7) versus autologe Spongiosaplastik. Unfallchirurg 2007;110:931–938.
4.
Calori GM, Albisetti W, Agus A, Iori S, Tagliabue L: Risk factors contributing to fracture non-unions. Injury 2007;38(suppl 2):S11–S18.
5.
Ai-Aql ZS, Alagl AS, Graves DT, Gerstenfeld LC, Einhorn TA: Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 2008;87:107–118.
6.
Schmidmaier G, Capanna R, Wildemann B, Beque T, Lowenberg D: Bone morphogenetic proteins in critical-size bone defects: what are the options? Injury 2009;40(suppl 3):S39–S43.
7.
Boden SD: Biology of lumbar spine fusion and use of bone graft substitutes: present, future, and next generation. Tissue Eng 2000;6:383–399.
8.
Younger EM, Chapman MW: Morbidity at bone graft donor sites. J Orthop Trauma 1989;3:192–195.
9.
Ahlmann E, Patzakis M, Roidis N, Shepherd L, Holtom P: Comparison of anterior and posterior iliac crest bone grafts in terms of harvest-site morbidity and functional outcomes. J Bone Joint Surg Am 2002;84-A:716–720.
10.
Arrington ED, Smith WJ, Chambers HG, Bucknell AL, Davino NA: Complications of iliac crest bone graft harvesting. Clin Orthop Relat Res 1996;329:300–309.
11.
Niedhart C, Pingsmann A, Jürgens C, Marr A, Blatt R, Niethard FU: Complications after harvesting of autologous bone from the ventral and dorsal iliac crest – a prospective, controlled study (in German). Z Orthop Ihre Grenzgeb 2003;141:481–486.
12.
Sasso RC, LeHuec JC, Shaffrey C, Spine Interbody Research Group: Iliac crest bone graft donor site pain after anterior lumbar interbody fusion: a prospective patient satisfaction outcome assessment. J Spinal Disord Tech 2005;18(suppl):S77–S81.
13.
Silber JS, Anderson DG, Daffner SD, Brislin BT, Leland JM, Hilibrand AS, Vaccaro AR, Albert TJ: Donor site morbidity after anterior iliac crest bone harvest for single-level anterior cervical discectomy and fusion. Spine (Phila Pa 1976) 2003;28:134–139.
14.
De Long WG Jr, Einhorn TA, Koval K, McKee M, Smith W, Sanders R, Watson T: Bone grafts and bone graft substitutes in orthopaedic trauma surgery. A critical analysis. J Bone Joint Surg Am 2007;89:649–658.
15.
Logeart-Avramoglou D, Anagnostou F, Bizios R, Petite H: Engineering bone: challenges and obstacles. J Cell Mol Med 2005;9:72–84.
16.
Deutsch H: High-dose bone morphogenetic protein-induced ectopic abdomen bone growth. Spine J 2010;10:e1–e4.
17.
Smith DM, Cooper GM, Mooney MP, Marra KG, Losee JE: Bone morphogenetic protein 2 therapy for craniofacial surgery. J Craniofac Surg 2008;19:1244–1259.
18.
Carragee EJ, Hurwitz EL, Weiner BK: A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 2011;11:471–491.
19.
Fischer J, Kolk A, Wolfart S, Pautke C, Warnke PH, Plank C, Smeets R: Future of local bone regeneration – protein versus gene therapy. J Craniomaxillofac Surg 2011;39:54–64.
20.
Calori GM, Donati D, Di Bella C, Tagliabue L: Bone morphogenetic proteins and tissue engineering: future directions. Injury 2009;40(suppl 3):S67–S76.
21.
Quarto R, Mastrogiacomo M, Cancedda R, Kutepov SM, Mukhachev V, Lavroukov A, Kon E, Marcacci M: Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J Med 2001;344:385–386.
22.
Berner A, Pfaller C, Dienstknecht T, Zellner J, Müller M, Prantl L, Kujat R, Englert C, Fuechtmeier B, Nerlich M, Angele P: Arthroplasty of the lunate using bone marrow mesenchymal stromal cells. Int Orthop 2011;35:379–387.
23.
Cuomo AV, Virk M, Petrigliano F, Morgan EF, Lieberman JR: Mesenchymal stem cell concentration and bone repair: potential pitfalls from bench to bedside. J Bone Joint Surg Am 2009;91:1073–1083.
24.
Evans CH, Palmer GD, Pascher A, Porter R, Kwong FN, Gouze E, Gouze JN, Liu F, Steinert A, Betz O, Betz V, Vrahas M, Ghivizzani SC: Facilitated endogenous repair: making tissue engineering simple, practical, and economical. Tissue Eng 2007;13:1987–1993.
25.
Meijer GJ, de Bruijn JD, Koole R, van Blitterswijk CA: Cell-based bone tissue engineering. PLoS Med 2007;4:e9.
26.
Martin I, Baldomero H, Bocelli-Tyndall C, Slaper-Cortenbach I, Passweg J, Tyndall A: The survey on cellular and engineered tissue therapies in Europe in 2009. Tissue Eng Part A 2011;17:2221–2230.
27.
Martin I, Wendt D, Heberer M: The role of bioreactors in tissue engineering. Trends Biotechnol 2004;22:80–86.
28.
Martin I, Smith T, Wendt D: Bioreactor-based roadmap for the translation of tissue engineering strategies into clinical products. Trends Biotechnol 2009;27:495–502.
29.
Banfi A, Muraglia A, Dozin B, Mastrogiacomo M, Cancedda R, Quarto R: Proliferation kinetics and differentiation potential of ex vivo expanded human bone marrow stromal cells: implications for their use in cell therapy. Exp Hematol 2000;28:707–715.
30.
Braccini A, Wendt D, Jaquiery C, Jakob M, Heberer M, Kenins L, Wodnar-Filipowicz A, Quarto R, Martin I: Three-dimensional perfusion culture of human bone marrow cells and generation of osteoinductive grafts. Stem Cells 2005;23:1066–1072.
31.
Scherberich A, Galli R, Jaquiery C, Farhadi J, Martin I: Three-dimensional perfusion culture of human adipose tissue-derived endothelial and osteoblastic progenitors generates osteogenic constructs with intrinsic vascularisation capacity. Stem Cells 2007;25:1823–1829.
32.
Güven S, Mehrkens A, Saxer F, Schaefer DJ, Martinetti R, Martin I, Scherberich A: Engineering of large osteogenic grafts with rapid engraftment capacity using mesenchymal and endothelial progenitors from human adipose tissue. Biomaterials 2011;32:5801–5809.
33.
Salter E, Goh B, Hung B, Hutton D, Ghone N, Grayson WL: Bone tissue engineering bioreactors: a role in the clinic? Tissue Eng Part B Rev 2012;18:62–75.
34.
Cox G, McGonagle D, Boxall SA, Buckley CT, Jones E, Giannoudis PV: The use of the reamer-irrigator-aspirator to harvest mesenchymal stem cells. J Bone Joint Surg Br 2011;93:517–524.
35.
Stafford PR, Norris BL: Reamer-irrigator-aspirator bone graft and bi Masquelet technique for segmental bone defect nonunions: a review of 25 cases. Injury 2010;41(suppl 2):S72–S77.
36.
Aslan H, Zilberman Y, Kandel L, Liebergall M, Oskouian RJ, Gazit D, Gazit Z: Osteogenic differentiation of noncultured immunoisolated bone marrow-derived CD105+ cells. Stem Cells 2006;24:1728–1737.
37.
Braccini A, Wendt D, Farhadi J, Schaeren S, Heberer M, Martin I: The osteogenicity of implanted engineered bone constructs is related to the density of clonogenic bone marrow stromal cells. J Tissue Eng Regen Med 2007;1:60–65.
38.
Fraser JK, Wulur I, Alfonso Z, Hedrick MH: Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol 2006;24:150–154.
39.
Housman TS, Lawrence N, Mellen BG, et al: The safety of liposuction: results of a national survey. Dermatol Surg 2002;28:971–978.
40.
Helder MN, Knippenberg M, Klein-Nulend J, Wuisman PI: Stem cells from adipose tissue allow challenging new concepts for regenerative medicine. Tissue Eng 2007;13:1799–1808.
41.
Vergroesen PP, Kroeze RJ, Helder MN, Smit TH: The use of poly(L-lactide-co-caprolactone) as a scaffold for adipose stem cells in bone tissue engineering: application in a spinal fusion model. Macromol Biosci 2011;11:722–730.
42.
Müller AM, Mehrkens A, Schäfer DJ, Jaquiery C, Güven S, Lehmicke M, Martinetti R, Farhadi I, Jakob M, Scherberich A, Martin I: Towards an intraoperative engineering of osteogenic and vasculogenic grafts from the stromal vascular fraction of human adipose tissue. Eur Cell Mater 2010;19:127–135.
43.
Miranville A, Heeschen C, Sengenès C, Curat CA, Busse R, Bouloumié A: Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004;110:349–355.
44.
Scotti C, Tonnarelli B, Papadimitropoulos A, Scherberich A, Schaeren S, Schauerte A, Lopez-Rios J, Zeller R, Barbero A, Martin I: Recapitulation of endochondral bone formation using human adult mesenchymal stem cells as a paradigm for developmental engineering. Proc Natl Acad Sci USA 2010;107:7251–7256.
45.
Jukes JM, Both SK, Leusink A, Sterk LM, van Blitterswijk CA, de Boer J: Endochondral bone tissue engineering using embryonic stem cells. Proc Natl Acad Sci USA 2008;105:6840–6845.
46.
Gawlitta D, Farrell E, Malda J, Creemers LB, Alblas J, Dhert WJ: Modulating endochondral ossification of multipotent stromal cells for bone regeneration. Tissue Eng Part B Rev 2010;16:385–395.
47.
Lenas P, Moos M, Luyten FP: Developmental engineering: a new paradigm for the design and manufacturing of cell-based products. Part I: from three-dimensional cell growth to biomimetics of in vivo development. Tissue Eng Part B Rev 2009;15:381–394.
48.
Lenas P, Moos M, Luyten FP: Developmental engineering: a new paradigm for the design and manufacturing of cell-based products. Part II: from genes to networks: tissue engineering from the viewpoint of systems biology and network science. Tissue Eng Part B Rev 2009;15:395–422.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
